For research use only. Not for therapeutic Use.
6RK73 is a covalent irreversible and specific UCHL1 inhibitor with an IC50 of 0.23 µM. 6RK73 shows almost no inhibition of UCHL3 (IC50=236 µM). 6RK73 specifically inhibit UCHL1 activity in breast cancer[1].
6RK73 (5 μM; 1-3 hours) treatment displays strong inhibition of the TGFβ-induced pSMAD2 and pSMAD3, and a decrease of TβRI and total SMAD protein levels in MDA-MB-436 cells[1].
6RK73(5 μM; 24-48 hours) results migration significantly slower than the DMSO control group in MDA-MB-436 cells[1].
6RK73 displays a potent inhibition of breast cancer extravasation in zebrafish[1].
| Catalog Number | I017355 |
| CAS Number | 1895050-66-4 |
| Synonyms | (3S)-1-cyano-N-(5-morpholin-4-yl-1,3-thiazol-2-yl)pyrrolidine-3-carboxamide |
| Molecular Formula | C13H17N5O2S |
| Purity | ≥95% |
| InChI | InChI=1S/C13H17N5O2S/c14-9-17-2-1-10(8-17)12(19)16-13-15-7-11(21-13)18-3-5-20-6-4-18/h7,10H,1-6,8H2,(H,15,16,19)/t10-/m0/s1 |
| InChIKey | ONIHSXKWNFYNNS-JTQLQIEISA-N |
| SMILES | C1CN(CC1C(=O)NC2=NC=C(S2)N3CCOCC3)C#N |
| Reference | [1]. Liu S, et al. Deubiquitinase activity profiling identifies UCHL1 as a candidate oncoprotein that promotes TGFβ-induced breast cancer metastasis. Clin Cancer Res. 2019 Dec 19. pii: clincanres.1373.2019. |
